Drug Target Review

JULY 13, 2023

The company developed methods to identify disease-driving condensates, model them, and create systems for effective drug discovery targeting these condensates. The aim is to establish condensate biology as a fundamental branch of cell biology – “cell biology 2.0”

Disease 98

Disease Small Molecule Cell Biology Drugs 98

Broad Institute

NOVEMBER 2, 2023

At the Broad Institute of MIT and Harvard, a group of researchers, software engineers, administrators, and communicators (yes, us) has been exploring the use of these chatbots and similar tools, surveying the community and developing recommendations. Can generative AI be useful for hypothesis generation?

Research 124

Research Engineering Science Cell Biology 124

Broad Institute

OCTOBER 11, 2023

By Allessandra DiCorato October 11, 2023 In 2011, Robert Manguso was working in a cell biology lab when his mother was diagnosed with Merkel cell carcinoma, a rare and aggressive skin cancer. These cells also express the Cas9 protein, which helps disable the genes targeted by the guide RNAs.

Research 137

Research Immune Response Clinical Trials Therapies 137

Elrig

APRIL 29, 2024

Driven by an interest in drug discovery Millie joined AstraZeneca after completion of her PhD at the end of 2020. As an early career professional (ECP) herself, Millie is currently a member of ELRIG’s ECP workgroup, and is excited to co-chair her first webinar.

Bioinformatics 59

Bioinformatics Drugs Molecular Biology Cell Based Assays 59

Drug Target Review

JANUARY 16, 2025

Researchers have shown that cell permeability can be improved by designing macrocyclic peptides whose structure includes amide (NH) groups that are engaged in internal hydrogen bonding interactions. 12 Ring bridging strategies have also been effective in addressing permeability, as seen with MK-0616.

Drug Development 52

Drug Development Small Molecule Drugs FDA Approval 52

SugarCone Biotech

MAY 28, 2019

Learnings regarding immune geography and cell:cell contact are increasingly important as we consider how best to advance cell therapies for diverse hematologic malignancies and solid tumors ( www.aletabio.com ). This was an interesting finding and one that I think remains under-appreciated by the immuno-oncology drug development field.

Immune Response 52

Immune Response Therapies Engineering Drug Development 52